GSK reports Q2 results on July 29 having just delivered its strongest week since early 2026, and the options market is finally reflecting that shift in mood.
The most striking change since the last preview is in options positioning — and it now runs in the opposite direction. The put/call ratio has dropped to 1.12, more than two standard deviations below its 20-day average of 1.31, touching its lowest reading since the 52-week low of 0.40 briefly flashed in mid-June. For months, options traders consistently favoured puts over calls. That posture has unwound sharply in a single session. The stock itself reinforces the turn: GSK closed at $53.71, up 3.3% on Monday and 5.8% on the week — a meaningful reversal from the laggard positioning that defined the stock through most of July.
The lending market remains exactly where it has been, and that consistency is its own signal. Availability has tightened modestly to 167% from around 200% earlier in the month — meaning there are still roughly 1.7 shares available to borrow for every one already lent out, well within normal range. Short interest has climbed about 68% in share terms over the past month, but borrowing costs remain negligible at 0.63%. There is no squeeze dynamic, no meaningful cost pressure, and no sign that short sellers are positioned to cause disruption around the print. The short score of 47 is mid-range and unremarkable.
The analyst picture is mixed, though the most recent action skews cautious. Citigroup reinstated coverage last Friday with a Neutral rating, adding a measured voice to a Street that already includes a Barclays Underweight (initiated in January) and a Goldman Sachs Neutral from 2024. Jefferies swings between the two camps — it downgraded to Hold in late 2024 before assuming a Buy in October 2025. The consensus price target data is too stale to cite reliably given the stock's current price of $53.71. On valuation, GSK trades at roughly 10.4x trailing earnings and 14x EV/EBITDA — not demanding for a large-cap pharma, but not obviously cheap either. The dividend score ranks in the 93rd percentile across the ORTEX universe, reflecting an above-average income profile that underpins the bull case for income-oriented holders. A recent note flagged strong interim results, raised full-year guidance, and pipeline momentum in oncology and vaccines as the primary drivers of the rally. The bear case centres on patent cliff exposure and lingering Zantac litigation overhang.
The Q2 print will therefore test whether the guidance raise and pipeline progress announced informally ahead of results can hold up under scrutiny — and whether a stock that spent most of 2026 as a pharma underperformer has genuinely turned the corner or simply caught a bid into the event.
See the live data behind this article on ORTEX.
Open GSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
